---
figid: PMC9168966__MOL2-16-2117-g004
pmcid: PMC9168966
image_filename: MOL2-16-2117-g004.jpg
figure_link: /pmc/articles/PMC9168966/figure/mol213146-fig-0002/
number: Fig. 2
figure_title: ''
caption: TGF‐β and PD‐L1 signaling pathways are implicated in overlapping but nonredundant
  tumor survival mechanisms, such that simultaneous inhibition may enhance antitumor
  activity over inhibition of either pathway alone. PD‐1, programmed death 1; PD‐L1,
  programmed death ligand 1; TGF, transforming growth factor.
article_title: 'Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment.'
citation: James L. Gulley, et al. Mol Oncol. 2022 Jun;16(11):2117-2134.
year: '2022'

doi: 10.1002/1878-0261.13146
journal_title: Molecular Oncology
journal_nlm_ta: Mol Oncol
publisher_name: John Wiley and Sons Inc.

keywords:
- immune checkpoint inhibitor
- PD‐L1
- TGF‐β
- tumor microenvironment

---
